These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9294163)

  • 1. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding.
    Baca M; Scanlan TS; Stephenson RC; Wells JA
    Proc Natl Acad Sci U S A; 1997 Sep; 94(19):10063-8. PubMed ID: 9294163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the importance of second sphere residues in an esterolytic antibody by phage display.
    Arkin MR; Wells JA
    J Mol Biol; 1998 Dec; 284(4):1083-94. PubMed ID: 9837728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog.
    Takahashi-Ando N; Kakinuma H; Fujii I; Nishi Y
    J Immunol Methods; 2004 Nov; 294(1-2):1-14. PubMed ID: 15604011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody humanization using monovalent phage display.
    Baca M; Presta LG; O'Connor SJ; Wells JA
    J Biol Chem; 1997 Apr; 272(16):10678-84. PubMed ID: 9099717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of the immunological evolution of antibody 28B4.
    Yin J; Mundorff EC; Yang PL; Wendt KU; Hanway D; Stevens RC; Schultz PG
    Biochemistry; 2001 Sep; 40(36):10764-73. PubMed ID: 11535051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving catalytic antibodies in a phage-displayed combinatorial library.
    Fujii I; Fukuyama S; Iwabuchi Y; Tanimura R
    Nat Biotechnol; 1998 May; 16(5):463-7. PubMed ID: 9592396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistically different catalytic antibodies obtained from immunization with a single transition-state analog.
    Guo J; Huang W; Zhou GW; Fletterick RJ; Scanlan TS
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1694-8. PubMed ID: 7878042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of linkers for a catalytic single-chain antibody using phage display technology.
    Tang Y; Jiang N; Parakh C; Hilvert D
    J Biol Chem; 1996 Jun; 271(26):15682-6. PubMed ID: 8663068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: structural similarities in esterase-like catalytic antibodies.
    Charbonnier JB; Carpenter E; Gigant B; Golinelli-Pimpaneau B; Eshhar Z; Green BS; Knossow M
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11721-5. PubMed ID: 8524836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of functionally important residues in the pyridoxal-5'-phosphate-dependent catalytic antibody 15A9.
    Mouratou B; Stetefeld J
    Biochemistry; 2004 Jun; 43(21):6612-9. PubMed ID: 15157094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization.
    Miyashita H; Hara T; Tanimura R; Fukuyama S; Cagnon C; Kohara A; Fujii I
    J Mol Biol; 1997 Apr; 267(5):1247-57. PubMed ID: 9150409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro abzyme evolution to optimize antibody recognition for catalysis.
    Takahashi N; Kakinuma H; Liu L; Nishi Y; Fujii I
    Nat Biotechnol; 2001 Jun; 19(6):563-7. PubMed ID: 11385462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conformational effects in biological catalysis: an antibody-catalyzed oxy-cope rearrangement.
    Mundorff EC; Hanson MA; Varvak A; Ulrich H; Schultz PG; Stevens RC
    Biochemistry; 2000 Feb; 39(4):627-32. PubMed ID: 10651626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of antibody heavy chain CDR1 to digoxin binding analyzed by random mutagenesis of phage-displayed Fab 26-10.
    Short MK; Jeffrey PD; Kwong RF; Margolies MN
    J Biol Chem; 1995 Dec; 270(48):28541-50. PubMed ID: 7499368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A structural basis for transition-state stabilization in antibody-catalyzed hydrolysis: crystal structures of an abzyme at 1. 8 A resolution.
    Kristensen O; Vassylyev DG; Tanaka F; Morikawa K; Fujii I
    J Mol Biol; 1998 Aug; 281(3):501-11. PubMed ID: 9698565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
    Odenbaugh AL; Helms ED; Iverson BL
    Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of shape complementarity and catalytic efficiency from a primordial antibody template.
    Xu J; Deng Q; Chen J; Houk KN; Bartek J; Hilvert D; Wilson IA
    Science; 1999 Dec; 286(5448):2345-8. PubMed ID: 10600746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies.
    Kim SH; Schindler DG; Lindner AB; Tawfik DS; Eshhar Z
    Mol Immunol; 1997; 34(12-13):891-906. PubMed ID: 9464525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of catalytic antibody repertoire in autoimmune mice.
    Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):213-33. PubMed ID: 12379363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.